Latest News and Press Releases

On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019 Assuming positive OPTIMAL data, NDA submission expected...

WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

CHIASMA OPTIMAL Phase 3 topline data expected in Q3 2019 Company anticipates submitting U.S. NDA by year-end 2019, assuming positive CHIASMA OPTIMAL data, and if accepted for filing, further...

Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient in Phase 3 MPOWERED™...

Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:...

Presentation by Dr. Maria Fleseriu, a widely-published endocrinologist and recognized thought leader in the field of acromegaly WALTHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc....

Topline data now expected in September 2019, versus prior guidance of 4Q 2019 WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical...

Among the initial findings, some acromegaly patients managed by injectable somatostatin receptor ligands (SRLs) report symptoms that may interfere with daily life Treatment burden associated with...

NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...